why choose us

Clinical Trials Search

Showing 15,370 of 132,963 result(s)
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Status: Completed

Condition: Acute Myeloid Leukemia (AML)

Interventions: Dose level (-1) 80mg, (1) 120mg, (2) 120mg

Date: 2023-02-08

Metoclopramide in Upper Gastrointestinal Bleed

Status: Completed

Condition: Upper GI Bleeding

Interventions: IV Metoclopramide

Date: 2023-02-08

An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases

Status: Completed

Condition: Lupus Nephritis

Interventions: Administered by subcutaneous injection every 4 weeks

Date: 2023-02-08

A Study of TAS3351 in NSCLC Patients With EGFRmt

Status: Completed

Condition: Non-Small Cell Lung Cancer

Interventions: TAS3351 will be administered orally

Date: 2023-02-08

Dinner Time for Obesity and Prediabetes

Status: Completed

Condition: PreDiabetes

Interventions: Dinner before DLMO

Date: 2023-02-08

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Status: Completed

Condition: Relapsed or Refractory Acute Myeloid Leukemia

Interventions: Monoclonal antibody specific for LAIR-1

Date: 2023-02-08

Use of Ritual Epost Postnatal Multivitamins During the Postpartum Period

Status: NOT_YET_RECRUITING

Condition: Lactation Disorder - Postpartum Condition or Complication

Interventions: The Ritual Epre supplement is a commercially available multivitamin-mineral supplement designed for pregnant and lactating women.

Date: 2023-02-08

Anti-Inflammatory Challenge in Schizophrenia

Status: NOT_YET_RECRUITING

Condition: Schizophrenia

Interventions:

Infliximab has FDA approval for the treatment of rheumatoid arthritis and inflammatory bowel syndrome.
The current proposal represents the use

Date: 2023-02-08

Empower@Home:Connected - Feasibility and Preliminary Effect Study

Status: COMPLETED

Condition: Depression

Interventions: Cognitive behavioral therapy

Date: 2023-02-08

TRUDI: TDXD+Durva in HER2+;Low IBC

Status: Completed

Condition: Invasive Breast Cancer

Interventions: via IV, protocol determined dosage once per cycle up to eight cycles.
Each cycle will last for 21 days (three weeks).

Date: 2023-02-08